Regeneron Pharmaceuticals Inc logo

REGN - Regeneron Pharmaceuticals Inc News Story

$516.62 -0.6  -0.1%

Last Trade - 14/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £39.22bn
Enterprise Value £38.64bn
Revenue £6.55bn
Position in Universe 223rd / 6851

UPDATE 1-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

Thu 15th April, 2021 1:59pm
(Adds details of GSK-VIR deal, U.S. application, background on
monoclonal antibodies)
    April 15 (Reuters) - The European Medicines Agency said on
Thursday it is reviewing available data on the use of
GlaxoSmithKline's  GSK.L   monoclonal antibody to treat COVID-19
patients.
    The agency said its review of VIR-7831, which GSK is
developing with Vir Biotechnology Inc  VIR.O , will include data
from a study comparing its effect with that of a placebo in
patients with mild to moderate COVID-19 who were at high risk of
progressing to a more severe condition. (https://bit.ly/3n0spGx)
    While a more comprehensive rolling review is expected to
start at a later time, the agency said the current review will
provide European Union-wide recommendations for national
authorities who may take decisions on early use of the medicine.
    The companies reported in March that VIR-7831 reduced the
risk of hospitalisation and deaths among patients by 85%, based
on interim data from a study. 
    In late March, the companies filed an application to U.S.
regulators for emergency use authorization of VIR-7831 to treat
early-stage COVID-19 infections.  urn:newsml:reuters.com:*:nL4N2LO30F
    The United States has already recommended similar therapies
from Eli Lilly and Co  LLY.N  and Regeneron Pharmaceuticals Inc
 REGN.O . 
    European health regulators are reviewing treatments from
this class of medicines called monoclonal antibodies, which are
synthetically manufactured copies of the human body’s natural
infection-fighting proteins and are already being used to treat
some types of cancers. 
    GSK and Vir announced a partnership in 2020 to research
COVID-19 treatments, and earlier this year said they will expand
that partnership to develop monoclonal antibody treatments for
influenza and other respiratory illnesses.  urn:newsml:reuters.com:*:nL1N2KN0Z0

 (Reporting by Vishwadha Chander in Bengaluru; Editing by
Bernard Orr)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.